12.5 USD
+0.02 (+0.16%)
12.51 USD
+0.01 (+0.08%)
Overall PNT gets a fundamental rating of 5 out of 10. We evaluated PNT against 530 industry peers in the Biotechnology industry. PNT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PNT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PNT had positive earnings in the past year.
PNT had a positive operating cash flow in the past year.
1.2 Ratios
PNT has a better Return On Assets (20.22%) than 99.49% of its industry peers.
PNT's Return On Equity of 22.77% is amongst the best of the industry. PNT outperforms 97.81% of its industry peers.
With an excellent Return On Invested Capital value of 18.63%, PNT belongs to the best of the industry, outperforming 99.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.22% | ||
| ROE | 22.77% | ||
| ROIC | 18.63% |
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PNT (39.62%) is better than 99.33% of its industry peers.
PNT has a better Operating Margin (44.22%) than 98.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.22% | ||
| PM (TTM) | 39.62% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PNT has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
PNT has more shares outstanding than it did 1 year ago.
There is no outstanding debt for PNT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PNT has an Altman-Z score of 16.90. This indicates that PNT is financially healthy and has little risk of bankruptcy at the moment.
PNT has a better Altman-Z score (16.90) than 91.23% of its industry peers.
The Debt to FCF ratio of PNT is 0.06, which is an excellent value as it means it would take PNT, only 0.06 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.06, PNT belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that PNT is not too dependend on debt financing.
PNT has a Debt to Equity ratio (0.01) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.06 | ||
| Altman-Z | 16.9 |
ROIC/WACC1.67
WACC11.15%
2.3 Liquidity
PNT has a Current Ratio of 9.13. This indicates that PNT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PNT (9.13) is better than 73.52% of its industry peers.
PNT has a Quick Ratio of 9.13. This indicates that PNT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PNT (9.13) is better than 73.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.13 | ||
| Quick Ratio | 9.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 195.40% over the past year.
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
PNT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.94% yearly.
Based on estimates for the next years, PNT will show a very strong growth in Revenue. The Revenue will grow by 72.58% on average per year.
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.06, PNT is valued correctly.
PNT's Price/Earnings ratio is rather cheap when compared to the industry. PNT is cheaper than 97.47% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.19, PNT is valued a bit cheaper.
PNT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | N/A |
4.2 Price Multiples
PNT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PNT is cheaper than 97.98% of the companies in the same industry.
PNT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PNT is cheaper than 97.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.37 | ||
| EV/EBITDA | 6.16 |
4.3 Compensation for Growth
PNT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as PNT's earnings are expected to grow with 36.93% in the coming years.
PEG (NY)1.64
PEG (5Y)N/A
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
5. Dividend
5.1 Amount
PNT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.5
+0.02 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.74%
Inst Owner Change0%
Ins Owners5.11%
Ins Owner Change0%
Market Cap1.33B
Revenue(TTM)243.80M
Net Income(TTM)96.60M
Analysts69.33
Price Target15.05 (20.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.81%
Min EPS beat(2)19.08%
Max EPS beat(2)24.55%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)312.79%
Min Revenue beat(2)211.88%
Max Revenue beat(2)413.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.94%
EPS NY rev (1m)0%
EPS NY rev (3m)12.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)83.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | N/A | ||
| P/S | 5.46 | ||
| P/FCF | 14.37 | ||
| P/OCF | 11.89 | ||
| P/B | 3.14 | ||
| P/tB | 3.14 | ||
| EV/EBITDA | 6.16 |
EPS(TTM)0.83
EY6.64%
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)0.87
FCFY6.96%
OCF(TTM)1.05
OCFY8.41%
SpS2.29
BVpS3.98
TBVpS3.98
PEG (NY)1.64
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.22% | ||
| ROE | 22.77% | ||
| ROCE | 24.56% | ||
| ROIC | 18.63% | ||
| ROICexc | 81.93% | ||
| ROICexgc | 81.93% | ||
| OM | 44.22% | ||
| PM (TTM) | 39.62% | ||
| GM | N/A | ||
| FCFM | 38.02% |
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.06 | ||
| Debt/EBITDA | 0.04 | ||
| Cap/Depr | 742.31% | ||
| Cap/Sales | 7.92% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.45% | ||
| Profit Quality | 95.96% | ||
| Current Ratio | 9.13 | ||
| Quick Ratio | 9.13 | ||
| Altman-Z | 16.9 |
F-Score6
WACC11.15%
ROIC/WACC1.67
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%
EBIT growth 1Y234.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.05%
EBIT Next 3Y38.92%
EBIT Next 5Y-10.32%
FCF growth 1Y261.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y371.58%
OCF growth 3YN/A
OCF growth 5YN/A
POINT BIOPHARMA GLOBAL INC / PNT FAQ
What is the ChartMill fundamental rating of POINT BIOPHARMA GLOBAL INC (PNT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PNT.
Can you provide the valuation status for POINT BIOPHARMA GLOBAL INC?
ChartMill assigns a valuation rating of 5 / 10 to POINT BIOPHARMA GLOBAL INC (PNT). This can be considered as Fairly Valued.
What is the profitability of PNT stock?
POINT BIOPHARMA GLOBAL INC (PNT) has a profitability rating of 4 / 10.
What is the financial health of POINT BIOPHARMA GLOBAL INC (PNT) stock?
The financial health rating of POINT BIOPHARMA GLOBAL INC (PNT) is 8 / 10.